Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 1.00 |
| ▸ | GAA | P10253 | 9/20 | 1.00 |
| ▸ | GLA | P06280 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | NPBWR1 | P48145 | 1/20 | 1.00 |
| ▸ | CA9 | Q16790 | 3/20 | 0.71 |
| ▸ | F2 | P00734 | 1/20 | 0.70 |
| ▸ | AR | P10275 | 1/20 | 0.68 |
| ▸ | CA12 | O43570 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 6/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | IGLV6-57 | P01721 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4386227 | 0.88 | KDM4E (0.79) | KDM4EALDH1A1GAAGLAKMT2A | |
| SCHEMBL27860823 | 0.87 | KDM4E (0.77) | KDM4EALDH1A1GAAGLAKMT2A | |
| SCHEMBL26236223 | 0.86 | KDM4E (0.74) | KDM4EALDH1A1GAAGLAKMT2A | |
| SCHEMBL29676524 | 0.85 | KMT2A (0.74) | KDM4EALDH1A1GAAGLAKMT2A | |
| SCHEMBL27326021 | 0.85 | ALDH1A1 (0.72) | KDM4EALDH1A1GAAGLAKMT2A | |
| SCHEMBL27326912 | 0.84 | ALDH1A1 (0.71) | KDM4EALDH1A1GAAGLAKMT2A | |
| SCHEMBL6265592 | 0.83 | KDM4E (0.70) | KDM4EALDH1A1GAAGLAKMT2A | |
| SCHEMBL29700876 | 0.82 | ALDH1A1 (0.69) | KDM4EALDH1A1GAAGLAKMT2A | |
| SCHEMBL25054015 | 0.82 | KMT2A (1.00) | KDM4EALDH1A1GAAGLAKMT2A | |
| SCHEMBL335474 | 0.82 | KDM4E (1.00) | KDM4EALDH1A1GAAGLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5342691-A | Phenyl (meth) acrylate type polymer or copolymer with UV absorber | ROHM GMBH CHEMISCHE FABRIK (DE) | 1994-08-30 | — | — | US | claimed |
| US-20120046238-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-02-23 | — | — | US | disclosed |
| US-20120046238-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-02-23 | — | — | US | disclosed |
| US-8058427-B2 | Coumarin compounds and their use for treating cancer | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2011-11-15 | — | — | US | disclosed |
| US-8058427-B2 | Coumarin compounds and their use for treating cancer | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2011-11-15 | — | — | US | disclosed |
| US-20090312317-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING CANCER | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-12-17 | — | — | US | disclosed |
| US-20090312317-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING CANCER | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-12-17 | — | — | US | disclosed |
| WO-2009152210-A2 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING CANCER | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-12-17 | — | — | WO | disclosed |
| US-20090312406-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-12-17 | — | — | US | disclosed |
| US-20090312406-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-12-17 | — | — | US | disclosed |
| US-20090312406-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312406-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION | C1R, CYP3A4, CYP3A7 | KDM4E 3612/4885ALDH1A1 718/4885GAA 1341/4885 |
| US-20120046238-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION | C1R, CYP3A4, CYP3A7 | KDM4E 3612/4885ALDH1A1 718/4885GAA 1341/4885 |
| US-20090312317-A1 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING CANCER | SIRT3, CBR3, RDX | KDM4E 2566/4885ALDH1A1 175/4885GAA 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.